How long does it take to become resistant to Osimertinib?

Patients treated with Osimertinib typically develop resistance within about 10 months. Resistance mediated by the exon 20 C797S mutation is responsible for the majority of resistance cases, which has led to multiple attempts using non-ATP competitive or allosteric inhibitors in an attempt to counteract this acquired resistance by targeting other regions of the RTK kinase domain.

Resistance to osimertinib has become a major obstacle in the treatment of non-small cell lung cancer with EGFR mutations. A study that received osimertinib showed that 31 patients achieved objective tumor response, with an objective response rate of 71.1% and a median disease-free survival of 9.0 months. Fisher's exact test and chi-square test showed that the type of EGFR mutation as well as age, gender, race, smoking history, previous history of EGFR-TKI targeted therapy, radiotherapy and chemotherapy were not associated with tumor response to osimertinib, and Kaplan-Meier curves showed that the above factors were not associated with PFS.

OsimertinibThe original drug has been launched in China and has entered the scope of medical insurance. Its name is Osimertinib Mesylate Tablets. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. SpecificationThe price of 80mg*30 tablets per box is around RMB 5,000, which is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.